CN100383124C - 作为npy拮抗剂的喹啉衍生物 - Google Patents

作为npy拮抗剂的喹啉衍生物 Download PDF

Info

Publication number
CN100383124C
CN100383124C CNB038032805A CN03803280A CN100383124C CN 100383124 C CN100383124 C CN 100383124C CN B038032805 A CNB038032805 A CN B038032805A CN 03803280 A CN03803280 A CN 03803280A CN 100383124 C CN100383124 C CN 100383124C
Authority
CN
China
Prior art keywords
methyl
tetramethyleneimine
quinoline
alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038032805A
Other languages
English (en)
Chinese (zh)
Other versions
CN1627945A (zh
Inventor
帕特里奥·马太
沃纳·米勒
沃纳·雷德哈特
马撒斯·亨里奇·莱太科文
菲利普·普夫勒格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN1627945A publication Critical patent/CN1627945A/zh
Application granted granted Critical
Publication of CN100383124C publication Critical patent/CN100383124C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNB038032805A 2002-02-04 2003-01-27 作为npy拮抗剂的喹啉衍生物 Expired - Fee Related CN100383124C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02001967.5 2002-02-04
EP02001967 2002-02-04

Publications (2)

Publication Number Publication Date
CN1627945A CN1627945A (zh) 2005-06-15
CN100383124C true CN100383124C (zh) 2008-04-23

Family

ID=27635782

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038032805A Expired - Fee Related CN100383124C (zh) 2002-02-04 2003-01-27 作为npy拮抗剂的喹啉衍生物

Country Status (19)

Country Link
US (1) US6696467B2 (enExample)
EP (1) EP1474145B1 (enExample)
JP (1) JP4216196B2 (enExample)
KR (1) KR100659428B1 (enExample)
CN (1) CN100383124C (enExample)
AR (1) AR038249A1 (enExample)
AT (1) ATE392897T1 (enExample)
AU (1) AU2003205679B2 (enExample)
BR (1) BR0307441A (enExample)
CA (1) CA2473181A1 (enExample)
DE (1) DE60320529T2 (enExample)
ES (1) ES2304498T3 (enExample)
MX (1) MXPA04007502A (enExample)
PE (1) PE20040120A1 (enExample)
PL (1) PL372295A1 (enExample)
RU (1) RU2298002C2 (enExample)
TW (1) TW200400032A (enExample)
UY (1) UY27646A1 (enExample)
WO (1) WO2003066055A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900226B2 (en) * 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
JP2004110367A (ja) * 2002-09-18 2004-04-08 Hitachi Ltd 記憶装置システムの制御方法、記憶制御装置、および記憶装置システム
US7317025B2 (en) 2003-09-24 2008-01-08 Johnson & Johnson Pharmaceutical Research & Development, Llc Non-peptidic NPY Y2 receptor inhibitors
KR101190912B1 (ko) 2003-11-19 2012-10-12 어레이 바이오파마 인크. Ｍｅｋ의 헤테로시클릭 억제제 및 그의 사용 방법
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
JP2009510132A (ja) * 2005-10-05 2009-03-12 メルク フロスト カナダ リミテツド ロイコトリエン生合成の阻害剤としての置換キノリン
RU2314295C2 (ru) * 2006-03-01 2008-01-10 Федеральное Государственное Образовательное Учреждение Высшего Профессионального Образования "Южный Федеральный Университет" 2-гетарилзамещенные 1,3-трополона, способ их получения (варианты) и фармацевтическая композиция антимикробного действия
WO2008141077A1 (en) * 2007-05-10 2008-11-20 Janssen Pharmaceutica N.V. Process for the preparation of tetrahydroquinolinyl, benzoxazine and benzothiazine derivatives
US8759348B2 (en) * 2007-05-17 2014-06-24 Helperby Therapeutics Limited Use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms
US20100125091A1 (en) 2008-11-14 2010-05-20 Gilead Palo Alto, Inc. Substituted heterocyclic compounds as ion channel modulators
PE20120693A1 (es) * 2009-06-29 2012-07-04 Agios Pharmaceuticals Inc Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
RU2620380C2 (ru) * 2010-12-03 2017-05-25 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Способы получения енаминов
CA2826648C (en) 2011-02-18 2019-06-04 Endo Pharmaceuticals Inc. Aminoindane compounds and use thereof in treating pain
AP2013007331A0 (en) 2011-06-24 2013-12-31 Amgen Inc TRPM8 antagonists and their use in treatments
EP2723718A1 (en) 2011-06-24 2014-04-30 Amgen Inc. Trpm8 antagonists and their use in treatments
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
WO2014028675A1 (en) 2012-08-15 2014-02-20 Endo Pharmaceuticals Inc. Use of aminoindane compounds in treating overactive bladder and interstitial cystitis
DK3102576T3 (da) 2014-02-03 2019-07-22 Vitae Pharmaceuticals Llc Dihydropyrrolopyridininhibitorer af ror-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
EP3331876B1 (en) 2015-08-05 2020-10-07 Vitae Pharmaceuticals, LLC Modulators of ror-gamma
EP3868750A1 (en) * 2015-11-20 2021-08-25 Vitae Pharmaceuticals, LLC Modulators of ror-gamma
TWI757266B (zh) 2016-01-29 2022-03-11 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
AU2017296392B2 (en) * 2016-07-14 2020-09-24 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
TWI774767B (zh) * 2017-05-12 2022-08-21 瑞士商多蒂孔股份有限公司 茚烷衍生物及其在有機電子產品的用途
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
CN115716826A (zh) 2017-07-24 2023-02-28 生命医药有限责任公司 RORγ的抑制剂
WO2019023278A1 (en) 2017-07-25 2019-01-31 Crinetics Pharmaceuticals, Inc. MODULATORS OF SOMATOSTATIN AND USES THEREOF
CN111163766A (zh) * 2017-08-17 2020-05-15 医肯纳肿瘤学公司 Ahr抑制剂和其用途
EP3740475B1 (en) * 2018-01-17 2022-04-20 Crinetics Pharmaceuticals, Inc. Process of making somatostatin modulators
RU2702648C1 (ru) * 2019-07-11 2019-10-09 федеральное государственное автономное образовательное учреждение высшего образования «Южный федеральный университет» 5,7-Ди(трет-бутил)-2-(4,7-дихлор-8-метил-5-нитрохинолин-2-ил)-4-нитро-1,3-трополон, обладающий цитотоксической активностью
EP3999509A4 (en) 2019-07-17 2023-07-19 Crinetics Pharmaceuticals, Inc. Crystalline forms of somatostatin modulators
JP7796115B2 (ja) 2020-09-09 2026-01-08 クリネティックス ファーマシューティカルズ，インク． ソマトスタチン調節因子の製剤

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4035367A (en) * 1974-09-09 1977-07-12 Sandoz, Inc. Hydroxyalkyl-substituted-amino-quinolines
WO1996037474A1 (en) * 1995-05-26 1996-11-28 Warner-Lambert Company Sulfonylquinolines as neuropeptide y1 antagonists
CN1245168A (zh) * 1993-10-28 2000-02-23 霍夫曼-拉罗奇有限公司 氨基喹啉衍生物
WO2002020488A2 (en) * 2000-09-06 2002-03-14 F. Hoffmann-La Roche Ag Quinoline and quinazoline derivatives as ligands for the neuropeptide y receptor
WO2002094789A1 (en) * 2001-05-21 2002-11-28 F. Hoffmann-La Roche Ag Quinoline derivatives as ligands for the neuropeptide y receptor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1270837A (en) 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
CA2035972C (en) 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
RU2161967C2 (ru) * 1994-08-18 2001-01-20 Дзе Проктер Энд Гэмбл Компани Соединения 7-(2-имидазолиниламино) хинолина, пригодные в качестве агонистов альфа-2-адренорецептора
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
CA2340056C (en) 1998-08-14 2007-01-09 F. Hoffmann-La Roche Ag Pharmaceutical compositions containing lipase inhibitors
PT1105123E (pt) 1998-08-14 2004-08-31 Hoffmann La Roche Composicoes farmaceuticas contendo inibidores da lipase e quitosano
DE10064105A1 (de) * 2000-12-21 2002-06-27 Bayer Ag Neue Substituierte Imidazotriazinone

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4035367A (en) * 1974-09-09 1977-07-12 Sandoz, Inc. Hydroxyalkyl-substituted-amino-quinolines
CN1245168A (zh) * 1993-10-28 2000-02-23 霍夫曼-拉罗奇有限公司 氨基喹啉衍生物
WO1996037474A1 (en) * 1995-05-26 1996-11-28 Warner-Lambert Company Sulfonylquinolines as neuropeptide y1 antagonists
WO2002020488A2 (en) * 2000-09-06 2002-03-14 F. Hoffmann-La Roche Ag Quinoline and quinazoline derivatives as ligands for the neuropeptide y receptor
WO2002094789A1 (en) * 2001-05-21 2002-11-28 F. Hoffmann-La Roche Ag Quinoline derivatives as ligands for the neuropeptide y receptor

Also Published As

Publication number Publication date
JP2005523901A (ja) 2005-08-11
EP1474145A1 (en) 2004-11-10
MXPA04007502A (es) 2004-11-10
US20030153553A1 (en) 2003-08-14
AR038249A1 (es) 2005-01-05
EP1474145B1 (en) 2008-04-23
PE20040120A1 (es) 2004-03-06
BR0307441A (pt) 2005-01-04
PL372295A1 (en) 2005-07-11
DE60320529T2 (de) 2009-06-10
CA2473181A1 (en) 2003-08-14
KR20040081484A (ko) 2004-09-21
KR100659428B1 (ko) 2006-12-19
CN1627945A (zh) 2005-06-15
WO2003066055A1 (en) 2003-08-14
RU2004126936A (ru) 2005-10-10
UY27646A1 (es) 2003-08-29
ES2304498T3 (es) 2008-10-16
TW200400032A (en) 2004-01-01
RU2298002C2 (ru) 2007-04-27
AU2003205679A1 (en) 2003-09-02
ATE392897T1 (de) 2008-05-15
DE60320529D1 (de) 2008-06-05
US6696467B2 (en) 2004-02-24
AU2003205679B2 (en) 2006-06-29
JP4216196B2 (ja) 2009-01-28

Similar Documents

Publication Publication Date Title
JP4216196B2 (ja) Ｎｐｙアンタゴニストとしてのキノリン誘導体
KR100621272B1 (ko) 퀴놀린 및 퀴나졸린 유도체
KR100621287B1 (ko) 신경 펩타이드 ｙ 수용체에 대한 리간드로서의 퀴놀린유도체
KR100514148B1 (ko) 아실-피페라지닐-피리미딘 유도체 및 이의 제조방법 및약물로써의 용도
JP2009280587A (ja) セロトニン５ｈｔ−２レセプターのアゴニストまたはアンタゴニストとしてのピペラジニルピラジン化合物
CZ20013319A3 (cs) Nové amidové deriváty, způsob jejich přípravy a farmaceutická kompozice, která je obsahuje
JPH10500989A (ja) ５ｈｔ１ａ拮抗薬としてのピペラジン誘導体
US5286735A (en) Derivatives of 4-aminomethylpiperidine, their preparation and their use as therapeutics
JP2873025B2 (ja) １‐［モノ―もしくはビス（トリフルオロメチル）‐２‐ピリジニル］ピペラジンを含有する薬剤組成物
WO2004078723A1 (ja) ４－ピリジルアルキルチオ基を置換基として有する新規化合物
JP2004507527A5 (enExample)
CN102781914A (zh) 吲哚衍生物
US20040248883A1 (en) Novel heteroaryl derivatives, their preparation and use
ZA200308637B (en) 4-[Phenyl-(piperidin-4-yl)-amino]-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders.
JP2003502317A (ja) 新規化合物、その使用および製造
CN101128447A (zh) 二芳基甲基哌嗪衍生物，其制备及其用途
JP3987113B2 (ja) 抗高血圧活性を有する新規キナゾリン―４―アミノ―２―（ピペリジン―１―イル―４―置換）誘導体並びにその製造法および医薬用途
JP2003277263A (ja) 医薬組成物
TWI291958B (en) Pyrazinyl-piperazine compounds, their use in the treatment of serotonin related diseases, and their preparation
JP2000063277A (ja) Ｃｒｆ受容体拮抗薬

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080423

Termination date: 20100301